TherapeuticsMD (TXMD) Competitors $1.10 -0.01 (-0.90%) Closing price 08/4/2025 04:00 PM EasternExtended Trading$1.11 +0.01 (+0.91%) As of 08/4/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TXMD vs. PDSB, IPSC, PYRGF, ATNM, RENB, ANL, CALC, PRLD, KALA, and CGTXShould you be buying TherapeuticsMD stock or one of its competitors? The main competitors of TherapeuticsMD include PDS Biotechnology (PDSB), Century Therapeutics (IPSC), PyroGenesis Canada (PYRGF), Actinium Pharmaceuticals (ATNM), Renovaro (RENB), Adlai Nortye (ANL), CalciMedica (CALC), Prelude Therapeutics (PRLD), KALA BIO (KALA), and Cognition Therapeutics (CGTX). These companies are all part of the "pharmaceutical products" industry. TherapeuticsMD vs. Its Competitors PDS Biotechnology Century Therapeutics PyroGenesis Canada Actinium Pharmaceuticals Renovaro Adlai Nortye CalciMedica Prelude Therapeutics KALA BIO Cognition Therapeutics TherapeuticsMD (NASDAQ:TXMD) and PDS Biotechnology (NASDAQ:PDSB) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, valuation, profitability, dividends, analyst recommendations, risk, earnings and institutional ownership. Does the media prefer TXMD or PDSB? In the previous week, TherapeuticsMD's average media sentiment score of 0.00 equaled PDS Biotechnology'saverage media sentiment score. Company Overall Sentiment TherapeuticsMD Neutral PDS Biotechnology Neutral Which has more volatility and risk, TXMD or PDSB? TherapeuticsMD has a beta of 0.42, suggesting that its share price is 58% less volatile than the S&P 500. Comparatively, PDS Biotechnology has a beta of 0.95, suggesting that its share price is 5% less volatile than the S&P 500. Do insiders and institutionals have more ownership in TXMD or PDSB? 30.7% of TherapeuticsMD shares are held by institutional investors. Comparatively, 26.8% of PDS Biotechnology shares are held by institutional investors. 2.3% of TherapeuticsMD shares are held by insiders. Comparatively, 9.2% of PDS Biotechnology shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Do analysts prefer TXMD or PDSB? PDS Biotechnology has a consensus price target of $9.00, suggesting a potential upside of 703.57%. Given PDS Biotechnology's stronger consensus rating and higher probable upside, analysts clearly believe PDS Biotechnology is more favorable than TherapeuticsMD.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TherapeuticsMD 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00PDS Biotechnology 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33 Which has better valuation & earnings, TXMD or PDSB? TherapeuticsMD has higher revenue and earnings than PDS Biotechnology. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTherapeuticsMD$1.76M7.23-$2.18MN/AN/APDS BiotechnologyN/AN/A-$37.61M-$0.94-1.19 Is TXMD or PDSB more profitable? PDS Biotechnology has a net margin of 0.00% compared to TherapeuticsMD's net margin of -114.07%. TherapeuticsMD's return on equity of -7.86% beat PDS Biotechnology's return on equity.Company Net Margins Return on Equity Return on Assets TherapeuticsMD-114.07% -7.86% -5.46% PDS Biotechnology N/A -150.59%-69.15% SummaryPDS Biotechnology beats TherapeuticsMD on 7 of the 12 factors compared between the two stocks. Get TherapeuticsMD News Delivered to You Automatically Sign up to receive the latest news and ratings for TXMD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TXMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TXMD vs. The Competition Export to ExcelMetricTherapeuticsMDMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$12.85M$2.50B$5.51B$9.35BDividend YieldN/A1.78%4.73%4.15%P/E RatioN/A9.0129.1424.41Price / Sales7.23717.24451.90108.38Price / CashN/A22.2824.4827.20Price / Book0.465.008.525.77Net Income-$2.18M$31.61M$3.24B$264.99M7 Day Performance-5.98%-3.00%-0.79%-2.13%1 Month Performance-1.79%5.68%8.00%7.06%1 Year Performance-31.25%0.43%27.38%20.80% TherapeuticsMD Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TXMDTherapeuticsMD0.612 of 5 stars$1.10-0.9%N/A-31.3%$12.85M$1.76M0.00420Upcoming EarningsPDSBPDS Biotechnology1.5013 of 5 stars$1.18flat$9.00+662.7%-65.2%$53.94MN/A-1.2620IPSCCentury Therapeutics3.4138 of 5 stars$0.64+2.3%$4.20+556.3%-71.2%$53.90M$6.59M-2.21170Positive NewsHigh Trading VolumePYRGFPyroGenesis Canada0.3666 of 5 stars$0.29-2.9%N/A-48.0%$53.85M$9.14M-4.7990High Trading VolumeATNMActinium Pharmaceuticals1.9862 of 5 stars$1.72-3.9%$4.00+132.6%-73.1%$53.66MN/A-1.2430Positive NewsRENBRenovaro0.5246 of 5 stars$0.32+2.1%N/A-50.6%$53.17MN/A-0.4120High Trading VolumeANLAdlai Nortye1.7678 of 5 stars$1.42-1.7%$9.00+536.0%-54.7%$53.14MN/A0.00127Upcoming EarningsGap UpCALCCalciMedica3.0016 of 5 stars$3.71-2.4%$16.00+331.3%-32.4%$53.09MN/A-2.3830Positive NewsUpcoming EarningsPRLDPrelude Therapeutics3.2983 of 5 stars$0.85-8.4%$4.50+428.1%-85.5%$52.51M$7M-0.50120Upcoming EarningsHigh Trading VolumeKALAKALA BIO3.5157 of 5 stars$7.93-2.0%$13.00+63.9%+26.3%$52.20M$3.89M-0.9630Upcoming EarningsCGTXCognition Therapeutics2.4041 of 5 stars$0.72-14.9%$2.83+296.2%-2.0%$52.07MN/A-0.9720Upcoming EarningsShort Interest ↑Gap Up Related Companies and Tools Related Companies PDS Biotechnology Alternatives Century Therapeutics Alternatives PyroGenesis Canada Alternatives Actinium Pharmaceuticals Alternatives Renovaro Alternatives Adlai Nortye Alternatives CalciMedica Alternatives Prelude Therapeutics Alternatives KALA BIO Alternatives Cognition Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TXMD) was last updated on 8/5/2025 by MarketBeat.com Staff From Our PartnersMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TherapeuticsMD, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TherapeuticsMD With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
